143 related articles for article (PubMed ID: 25604134)
61. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia.
Carroll RE; Benya RV; Turgeon DK; Vareed S; Neuman M; Rodriguez L; Kakarala M; Carpenter PM; McLaren C; Meyskens FL; Brenner DE
Cancer Prev Res (Phila); 2011 Mar; 4(3):354-64. PubMed ID: 21372035
[TBL] [Abstract][Full Text] [Related]
62. Mechanisms of skin aging induced by EGFR inhibitors.
Gerber PA; Buhren BA; Schrumpf H; Hevezi P; Bölke E; Sohn D; Jänicke RU; Belum VR; Robert C; Lacouture ME; Homey B
Support Care Cancer; 2016 Oct; 24(10):4241-8. PubMed ID: 27165055
[TBL] [Abstract][Full Text] [Related]
63. Serum Metabolite Profiles Are Altered by Erlotinib Treatment and the Integrin α1-Null Genotype but Not by Post-Traumatic Osteoarthritis.
Mickiewicz B; Shin SY; Pozzi A; Vogel HJ; Clark AL
J Proteome Res; 2016 Mar; 15(3):815-25. PubMed ID: 26784366
[TBL] [Abstract][Full Text] [Related]
64. A multi-scale approach to colorectal cancer: from a biochemical- interaction signaling-network level, to multi-cellular dynamics of malignant transformation. Interplay with mutations and onco-protein inhibitor drugs.
Tortolina L; Castagnino N; De Ambrosi C; Moran E; Patrone F; Ballestrero A; Parodi S
Curr Cancer Drug Targets; 2012 May; 12(4):339-55. PubMed ID: 22385511
[TBL] [Abstract][Full Text] [Related]
65. Early detection of colorectal cancer relapse by infrared spectroscopy in "normal" anastomosis tissue.
Salman A; Sebbag G; Argov S; Mordechai S; Sahu RK
J Biomed Opt; 2015 Jul; 20(7):75007. PubMed ID: 26178200
[TBL] [Abstract][Full Text] [Related]
66. Colorectal cancer through simulation and experiment.
Kershaw SK; Byrne HM; Gavaghan DJ; Osborne JM
IET Syst Biol; 2013 Jun; 7(3):57-73. PubMed ID: 24046975
[TBL] [Abstract][Full Text] [Related]
67. Lady with Long Eyelashes…!
Inamadar SS; Kumar NSP
Int J Trichology; 2022; 14(2):71-72. PubMed ID: 35531491
[TBL] [Abstract][Full Text] [Related]
68. Epidermal growth-factor receptor and erbb2 protein in colorectal tissue - comparison between cancer and normal mucosa.
Dittadi R; Gion M; Brazzale A; Nosadini A; Meo S; Tremolada C; Sicari U; Vinci I; Bruscagnin G
Int J Oncol; 1992 Oct; 1(5):587-91. PubMed ID: 21584585
[TBL] [Abstract][Full Text] [Related]
69. Response.
Repici A; Maselli R; Hassan C
Gastrointest Endosc; 2019 Sep; 90(3):533-534. PubMed ID: 31439134
[No Abstract] [Full Text] [Related]
70. Steps ahead in the treatment of advanced colorectal cancer: past, current and possible future scenarios.
Aprile G; Rihawi K; Scartozzi M; Bordonaro R
Future Oncol; 2015 Oct; 11(19):2625-2628. PubMed ID: 26357968
[No Abstract] [Full Text] [Related]
71. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).
Koeberle D; Betticher DC; von Moos R; Dietrich D; Brauchli P; Baertschi D; Matter K; Winterhalder R; Borner M; Anchisi S; Moosmann P; Kollar A; Saletti P; Roth A; Frueh M; Kueng M; Popescu RA; Schacher S; Hess V; Herrmann R
Ann Oncol; 2015 Apr; 26(4):709-714. PubMed ID: 25605741
[TBL] [Abstract][Full Text] [Related]
72. FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).
Aparicio T; Linot B; Le Malicot K; Bouché O; Boige V; François E; Ghiringhelli F; Legoux JL; Ben Abdelghani M; Phelip JM; Faroux R; Dahan L; Taieb J; Bedenne L
Dig Liver Dis; 2015 Apr; 47(4):271-2. PubMed ID: 25677925
[No Abstract] [Full Text] [Related]
73. Tissue-specific patterns of gene expression in the epithelium and stroma of normal colon in healthy individuals in an aspirin intervention trial.
Thomas SS; Makar KW; Li L; Zheng Y; Yang P; Levy L; Rudolph RY; Lampe PD; Yan M; Markowitz SD; Bigler J; Lampe JW; Potter JD
BMC Med Genet; 2015 Mar; 16():18. PubMed ID: 25927723
[TBL] [Abstract][Full Text] [Related]
74. Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial.
Lee DH; Lee JS; Wang J; Hsia TC; Wang X; Kim J; Orlando M
Cancer Res Treat; 2015 Oct; 47(4):616-29. PubMed ID: 25672577
[TBL] [Abstract][Full Text] [Related]
75. Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.
Ellingson BM; Kim E; Woodworth DC; Marques H; Boxerman JL; Safriel Y; McKinstry RC; Bokstein F; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
Int J Oncol; 2015 May; 46(5):1883-92. PubMed ID: 25672376
[TBL] [Abstract][Full Text] [Related]
76. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M
Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807
[TBL] [Abstract][Full Text] [Related]
77. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.
Gotink KJ; Rovithi M; de Haas RR; Honeywell RJ; Dekker H; Poel D; Azijli K; Peters GJ; Broxterman HJ; Verheul HM
Cell Oncol (Dordr); 2015 Apr; 38(2):119-29. PubMed ID: 25665527
[TBL] [Abstract][Full Text] [Related]
78. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).
Kotsakis A; Kentepozidis N; Emmanouilidis Ch; Polyzos A; Agelidou A; Vaslamatzis M; Chandrinos V; Agelaki S; Vamvakas L; Kalbakis K; Katsaounis P; Stoltidis D; Nintos G; Hatzidaki D; Vetsika EK; Mavroudis D; Georgoulias V
Lung Cancer; 2015 Apr; 88(1):57-62. PubMed ID: 25662596
[TBL] [Abstract][Full Text] [Related]
79. Non-cell autonomous effects of targeting inducible PGE2 synthesis during inflammation-associated colon carcinogenesis.
Nakanishi M; Perret C; Meuillet EJ; Rosenberg DW
Carcinogenesis; 2015 Apr; 36(4):478-86. PubMed ID: 25634334
[TBL] [Abstract][Full Text] [Related]
80. Evaluation of EGFR and COX pathway inhibition in human colon organoids of serrated polyposis and other hereditary cancer syndromes.
Kanth P; Hazel MW; Schell JC; Rutter J; Yao R; Mills AP; Delker DA
Fam Cancer; 2024 Apr; ():. PubMed ID: 38609520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
